Athersys Inc ATHX:NASDAQ

Last Price$1.03NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$1.02 (9)
Ask (Size)$1.03 (1)
Day Low / HighN/A - N/A
Volume1.8 M

View Biotechnology IndustryPeer Comparison as of 12/03/2021


Athersys Inc ( NASDAQ )

Price: $1.03
Change: -0.06 (5.50%)
Volume: 1.8 M
4:00PM ET 12/03/2021

Surface Oncology Inc ( NASDAQ )

Price: $5.24
Change: -0.39 (6.93%)
Volume: 697.1 K
4:00PM ET 12/03/2021

Co-Diagnostics Inc ( NASDAQ )

Price: $8.35
Change: -0.08 (0.95%)
Volume: 505.8 K
4:00PM ET 12/03/2021

Fortress Biotech Inc ( NASDAQ )

Price: $2.42
Change: -0.23 (8.68%)
Volume: 935.4 K
4:00PM ET 12/03/2021

9 Meters Biopharma Inc ( NASDAQ )

Price: $0.93
Change: -0.01 (1.09%)
Volume: 2.1 M
4:00PM ET 12/03/2021

Read more news Recent News

--BofA Securities Downgrades Athersys to Neutral From Buy; Price Target is $1.25
10:03AM ET 11/19/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (ATHX) ATHERSYS Reports Q3 Revenue $4.8M
4:08PM ET 11/15/2021 MT Newswires


Athersys Partner Completes Enrollment in Phase 2/3 Trial of MultiStem Cell Therapy for Ischemic Stroke; Shares Rise Midday
12:25PM ET 8/10/2021 MT Newswires

Athersys (ATHX) said Tuesday its partner Healios completed enrollment in its phase 2/3 trial in Japan evaluating the company's MultiStem cell therapy...

Athersys' Partner Reports Favorable Topline Results in Acute Respiratory Distress Syndrome Trial
2:37PM ET 8/06/2021 MT Newswires

Athersys (ATHX) said Friday that Healios, its partner in Japan, reported positive topline data from its clinical trial assessing the safety and efficacy of...

Company Profile

Business DescriptionAthersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH. View company web site for more details
Address3201 Carnegie Avenue
Cleveland, Ohio 44115-2634
Number of Employees75
Recent SEC Filing11/19/20214
President, Chief Executive & Operating OfficerWilliam B. J. Lehmann
Chief Financial & Accounting OfficerIvor MacLeod
Director, Chief Scientific Officer & Executive VPJohn J. Harrington
Head-Information Technology & CommunicationsRakesh Ramachandran

Company Highlights

Price Open$1.08
Previous Close$1.09
52 Week Range$0.92 - 3.03
Market Capitalization$242.3 M
Shares Outstanding235.2 M
SectorHealth Technology
Next Earnings Announcement03/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.41
Beta vs. S&P 500N/A
Revenue$24.3 M
Net Profit Margin-1,442.59%
Return on Equity-268.18%

Analyst Ratings as of 11/18/2021

Consensus RecommendationConsensus Icon
Powered by Factset